|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||N/A|
President Donald Trump repeated rhetoric from early in his presidency about drug prices being "out of control" and drugmakers "getting away with murder" on Monday, but said nothing ...
In 1H17, Novartis's (NVS) Sandostatin generated revenues of around $789 million, which reflected a ~4% decline on a year-over-year (or YoY) basis.
Merck's (MRK) Gardasil franchise includes vaccines for the prevention of certain strains of HPV infections that are sexually transmitted.
In 2Q17, Jazz Pharmaceuticals’ (JAZZ) Erwinaze generated revenues of ~$49 million, which represents a ~1% fall YoY and a ~4% fall QoQ.
Emerging markets such as China, Brazil, India, Russia, Mexico, and Turkey reported revenues of ~$1.4 billion during 2Q17, representing 2% growth at constant exchange rates from 2Q16.
As of August 30, 2017, GlaxoSmithKline is trading at a forward PE multiple of 13.3x, which is slightly lower than the industry average of 15.5x.
Johnson & Johnson’s (JNJ) medical devices segment reported revenue of $6.7 billion in 2Q17, a growth of 4.9% from the revenue of $6.4 billion reported in 2Q16. This figure included…
Jazz Pharmaceuticals (JAZZ) expects quarterly variability in Defitelio sales as the drug targets hepatic veno-occlusive disease (or VOD), an ultra-rare condition.
Defitelio could help Jazz Pharmaceuticals become a prominent player not only in the treatment but also in the prevention of post-HSCT complications.
For 2Q17, Jazz Pharmaceuticals (JAZZ) reported revenues close to $394 million, which represented a YoY growth of ~3% and sequential growth ~5%.
At constant exchange rates, Sanofi (SNY) reported revenue growth of ~5.5% between 2Q16 and 2Q17, with revenue rising to 8.7 billion euros from 8.1 billion euros. The above chart shows Sanofi’s…
Pfizer’s (PFE) innovative health business and essential health business are focusing on growth. To strengthen the innovative health business, the company is focusing on the development of new drugs…
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is enjoying a phenomenal 2017, up over 110% year-to-date. Vertex Pharmaceuticals specializes in cystic fibrosis (CF) treatment. Since its early days, Vertex has grown to become the world leader in CF treatment innovations, offering multiple patient options.
There are tons of reason to be skeptical about Valeant Pharmaceuticals Intl Inc (NYSE:VRX) stock ahead of its second-quarter fiscal 2017 earnings results before Tuesday’s opening bell. The embattled drugmaker continues to make operational improvements, including divesting various non-core assets to lower debts. Since falling to a 52-week low of $8.31 on April 24, Valeant stock has skyrocketed as much as 118%, reaching $18.17 on July 25.
Specialty pharma company Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) is set to report second-quarter fiscal 2017 earnings results Thursday before the opening bell. Despite the punishment TEVA stock has taken, the Israel-based company, which has beaten Wall Street’s earnings estimates for 10 straight quarters, has operated far better. Investors have had to absorb the recent departures of both Teva’s CEO and CFO.
Bristol-Myers Squibb’s (BMY) blockbuster drug Opdivo reported revenue of $1.2 billion in 2Q17, a 42% rise compared to $840 million in 2Q16.
For 2Q17, Basaglar sales were $86.6 million. Of that, $60.0 million was from sales in the US markets, while $27.0 million was from international sales.
Wall Street analysts expect AstraZeneca's top line to fall ~9.5% to $5.1 billion in 2Q17, compared to $5.6 billion in 2Q16. Its earnings per share are expected to be $0.42 in 2Q17.